These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Third-line treatment and von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284 [TBL] [Abstract][Full Text] [Related]
15. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006 [TBL] [Abstract][Full Text] [Related]
16. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of [ Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003 [TBL] [Abstract][Full Text] [Related]
18. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer. Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954 [TBL] [Abstract][Full Text] [Related]
19. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Jang A; Kendi AT; Sartor O Ther Adv Med Oncol; 2023; 15():17588359231157632. PubMed ID: 36895851 [TBL] [Abstract][Full Text] [Related]
20. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Rosar F; Dewes S; Ries M; Schaefer A; Khreish F; Maus S; Bohnenberger H; Linxweiler J; Bartholomä M; Ohlmann C; Ezziddin S Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):687-694. PubMed ID: 31901103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]